Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling Clinical Trial
Official title:
Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique
| Verified date | September 2017 |
| Source | University Hospital, Strasbourg, France |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms. Concordant with preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could be a marker of the disease activity and then a potential therapeutic target. In the present study, serum IL 26 level in lupus patients and control will be measured.
| Status | Terminated |
| Enrollment | 23 |
| Est. completion date | April 2015 |
| Est. primary completion date | April 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - diagnostic of Lupus according to ACR criteria ( four criteria are necessary) - age > 18 years old Exclusion Criteria: - treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study |
| Country | Name | City | State |
|---|---|---|---|
| France | Les Hôpitaux Universitaires de Strasbourg | Strasbourg | Bas Rhin |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Strasbourg, France |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Assess serum IL-26 as a biological marker of SLE compared with sera from control subjects | 2 years |